English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

atients undergoing percutaneous coronary intervention with a conventional bare-metal stent often require treatment for restenosis within 6 months of initial treatment due to neointimal hyperplasia. Drug-eluting stents (DES) have been developed for patients undergoing repeated treatments at short intervals because restenosis becomes refractory. DES have emerged as devices that can dramatically reduce the incidence of restenosis. However, there are concerns about the risk of stent thrombosis increasing because DES inhibit vascular smooth muscle cell proliferation and delay re-endothelialization. Once stent thrombosis occurs, it frequently causes serious complications including myocardial infarction and cardiac death. The greatest concern with DES is very late stent thrombosis (VLST), which occurs >1 year after DES implantation.

Speculative Mechanisms for Very Late Stent Thrombosis After Drug-Eluting Stent Implantation